Health CarePharmaceuticals & Biotechnology
  • Price (CHF)352.40
  • Today's Change1.30 / 0.37%
  • Shares traded26.28k
  • 1 Year change12.52%
  • Beta1.2018
Data delayed at least 15 minutes, as of Aug 23 2019 08:23 BST.
More ▼

Profile data is unavailable for this security.

About the company

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

  • Revenue in CHF (TTM)5.44bn
  • Net income in CHF644.00m
  • Incorporated2002
  • Employees14.70k
  • Location
    Lonza Group AGMuenchensteinerstrasse 38BASEL 4052SwitzerlandCHE
  • Phone+41 613168111
  • Fax+41 613169111
  • Websitehttps://www.lonza.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LONN:VTX since
Novartis AG-Fill & Finish Facility SteinAnnounced01 Jul 201901 Jul 2019Announced6.98%--
Octane Biotech IncDeal completed29 Oct 201829 Oct 2018Deal completed16.30%--
Data delayed at least 15 minutes, as of Aug 23 2019 08:23 BST.

Institutional shareholders

21.28%Per cent of shares held by top holders
HolderShares% Held
Artisan Partners LPas of 31 Dec 20182.25m3.02%
BlackRock Investment Management (UK) Ltd.as of 31 Jul 20192.05m2.76%
The Vanguard Group, Inc.as of 31 Jul 20192.02m2.71%
Fidelity Management & Research Co.as of 30 Jun 20191.75m2.35%
Norges Bank Investment Managementas of 17 Feb 20181.74m2.33%
TIAA-CREF Investment Management LLCas of 30 Jun 20191.46m1.97%
Invesco Advisers, Inc.as of 30 Jun 20191.25m1.68%
UBS AG (Investment Management)as of 07 Aug 20191.24m1.67%
Harding Loevner LPas of 30 Jun 20191.07m1.44%
Schroder Investment Management Ltd.as of 30 Jun 20191.02m1.37%
More ▼
Data from 31 Dec 2018 - 30 Jun 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.